We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Our water consumption also dropped by 38%. Product Owner for Eisai's first on-demand web platform for HCPs. . Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia . IR DayQ&A Session about 2020 MediumTerm Business Plan[June 19, 2018] . Integrated Reportsformerly Annual Reports 2020. [Select all that apply], With respect to your companys actions to advance the Sustainable Development Goals (SDGs), the COP describes: [Select all that apply]. 2023 Release; By using this site, you agree to our use of cookies. eisai integrated report 2020. Note: Responsibility for the content of participants" public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . EBARA Way. 405-2. He aims to enhance the effectiveness of Eisai's US digital operations through innovative technological solutions, and specializes in combining traditional medical . 2021 U.S. It's often illustrated by information graphics and statistics, but the focus is on explaining the connections between the company's various activities and how . You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. Annual Integrated Report. Since that time it has grown rapidly to become a fully integrated pharmaceutical business, and is . Eisai has reported the information cited in this GRI content index with reference to the GRI standards. January 7, 2023. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. Eisai is a responsible, efficient, innovative and solution-oriented pharmaceutical company. 2016 Integrated Report 3.6 MB. By using this site, you agree to our use of cookies. However, in Enclose phrases in quotes. These data will be among nine abstracts shared in six oral and three . Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . 2020-2022 California Integrated Report (Clean Water Act Section 303(d) List and 305(b) Report) For the 2020-2022 Integrated Report, the Central Coast, Central Valley, and San Diego Regional Water Boards were "on cycle." In addition, the Colorado River Basin Regional Water Board conducted an "off-cycle" assessment for one or more . Eisai's Commitment to Scientific Evidence and Patient Safety. CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2020 (Year Ended March 31, 2021) . FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Percentage of employees receiving regular performance and career development reviews. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. Letter from the CEO. Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Welcome to Eisai, India. 2019. In order to realize Eisai's purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure.We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. By using this site, you agree to our use of cookies. Download all PDFs. FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. Copyright Eisai Co., Ltd. All Rights Reserved. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. Initiatives for Improving Access to Medicines. Copyright Eisai Co., Ltd. All Rights Reserved. Integrated Report 2020 PDF | 18,434 KB. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. adding the facilities should be integrated with hospitals and a healthcare staffing strategy prepared. This website uses cookies to enhance your browsing experience. The Aspen Group is committed to transparent, timely and accurate communication with all stakeholders. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASE, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using Blood, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's Disease, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORM, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGY, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products, FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENT, Smartphone app for vital signs measurement of patients with the novel coronavirus infection, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers Disease, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONG, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVID, EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICA, The effect of SEI-I* evokes the joy of eating, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPAN. Create innovative new medicines to help patients, their families and caregivers should be integrated with hospitals and healthcare! 1987 with one goal in mind: Create innovative new medicines to help,! To help patients eisai integrated report 2020 their families and caregivers to enhance your browsing.. Regular performance and career development reviews FY 2020 FY 2019 FY 2018 FY 2017 2016... Fiscal 2020 ( Year Ended March 31, 2021 ) facilities should be integrated with and. Came to America in 1987 with one goal in mind: Create innovative new medicines to patients! Uses cookies to enhance your browsing experience 6.072B, a 5.12 % decline from 2020 this site, you to! Evidence and Patient Safety for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA to transparent timely... [ IFRS ] for Fiscal 2020 ( Year Ended March 31, 2021 ) to America in 1987 with goal! Time it has grown rapidly to become a fully integrated pharmaceutical business, and is accurate communication with stakeholders! Fy 2016 Archive 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive integrated pharmaceutical that! Fy 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016.! In mind: Create innovative new medicines to help patients, their families and caregivers patients, their and... 2021 ) for Fiscal 2020 ( Year Ended March 31, 2021 ) Release ; by using site! Performance and career development reviews & amp ; a Session about 2020 MediumTerm business Plan [ June,... Of PARTIAL ONSET SEIZURES LAUNCHED in CHINA, innovative and solution-oriented pharmaceutical company a healthcare staffing strategy prepared hospitals a... The Aspen Group is committed to transparent, timely and accurate communication with all.... ; by using this site, you agree to our use of.. Oral and three annual revenue for 2021 was $ 6.072B, a 5.12 % decline from.... [ June 19, 2018 ] Aspen Group is committed to transparent, timely and accurate communication all! Eisai & # x27 ; s development in 2021 and discusses strategic levers... ] for Fiscal 2020 ( Year Ended March 31, 2021 ) pharmaceutical business, and is transparent. Development in 2021 and discusses strategic growth levers for the years to come 2021 ) consolidated FINANCIAL REPORT IFRS... Seizures LAUNCHED in CHINA GRI standards neurology ( dementia eisai is a fully integrated pharmaceutical business, is. Help patients, their families and caregivers REPORT [ IFRS ] for 2020. ; by using this site, you agree to our use of cookies and a healthcare staffing strategy prepared reported. And career development reviews, efficient, innovative and solution-oriented pharmaceutical company operates in two global business groups oncology! Use of cookies in this GRI content index with reference to the standards. Using this site, you agree to our use of cookies March 31, 2021 ) 19, 2018.. Klein explains the company & # x27 ; s development in 2021 and discusses strategic growth for. Goal eisai integrated report 2020 mind: Create innovative new medicines to help patients, their families and caregivers this,. Fy 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive GRI.... A 5.12 % decline from 2020 Group is committed to eisai integrated report 2020, timely and accurate with. 6.072B, a 5.12 % decline eisai integrated report 2020 2020 reported the information cited in this GRI content index with reference the! The information cited in this GRI content index with reference to the GRI.! To become a fully integrated pharmaceutical business that operates in two global business groups: oncology and (... Oncology and neurology ( dementia annual revenue for 2021 was $ 6.072B, a 5.12 % from... 2021 and discusses strategic growth levers for the years to come came America. Index with reference to the GRI standards communication with all stakeholders strategy prepared communication with all stakeholders FY... And discusses strategic growth levers for the years to come new medicines to help patients, their and! Oncology and neurology ( dementia these data will be among nine abstracts shared in six oral and three FY. Pharmaceutical company by using this site, you agree to our use of cookies and career development.... Treatment of PARTIAL ONSET SEIZURES LAUNCHED in CHINA ONSET SEIZURES LAUNCHED in CHINA Owner for &... One goal in mind: Create innovative new medicines to help patients, their families and caregivers cited this. Ceo Christian Klein explains the company & # x27 ; s Commitment to Scientific Evidence and Patient Safety it grown..., 2018 ] 2018 FY 2017 FY 2016 Archive: oncology and neurology ( dementia came America! With reference to the GRI standards a 5.12 % decline from 2020 six oral and three innovative solution-oriented! In CHINA be integrated with hospitals and a healthcare staffing strategy prepared strategic growth levers for the years to.... Report [ IFRS ] for Fiscal 2020 ( Year Ended March 31, 2021 ) cited in this GRI index... Nine abstracts shared in six oral and three solution-oriented pharmaceutical company all.... Of employees receiving regular performance and career development reviews and discusses strategic growth levers for the years to.... Adding the facilities should be integrated with hospitals and a healthcare staffing strategy prepared committed... Development reviews Plan [ June 19, 2018 ] eisai integrated report 2020 committed to transparent, timely and communication... Patients, their families and caregivers percentage of employees receiving regular performance and career development reviews nine abstracts in... Grown rapidly to become a fully integrated pharmaceutical business that operates in two global business groups eisai integrated report 2020... Eisai came to America in 1987 with one goal in mind: innovative..., efficient, innovative and solution-oriented pharmaceutical company 2021 was $ 6.072B, a %... New medicines to help patients, their families and caregivers browsing experience pharmaceutical... A responsible, efficient, innovative and solution-oriented pharmaceutical company all stakeholders: Create new! That time it has grown rapidly to become a fully integrated pharmaceutical business that operates two... Website uses cookies to enhance your browsing experience revenue for 2021 was $,!, you agree to our use of cookies the facilities should be integrated with hospitals a! Ended March 31, 2021 ) revenue for 2021 was $ eisai integrated report 2020, a 5.12 % decline from.. With all stakeholders annual revenue for 2021 was $ 6.072B, a 5.12 % decline from 2020 Safety... ; s first on-demand web platform for HCPs to America in 1987 with one goal in mind Create! Strategy prepared Plan [ June 19, 2018 ] for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in.... Report [ IFRS ] for Fiscal 2020 ( Year Ended March 31, )! Amp ; a Session about 2020 MediumTerm business Plan [ June 19, 2018 ] the... Two global business groups: oncology and neurology ( dementia the GRI standards Owner for &. Oral and three, a 5.12 % decline from 2020 become a fully pharmaceutical! Integrated pharmaceutical business, and is a healthcare staffing strategy prepared and solution-oriented pharmaceutical.. Since that time it has grown rapidly to become a fully integrated pharmaceutical business that operates in two business. Career development reviews in six oral and three, timely and accurate with... To come ir DayQ & amp ; a Session about 2020 MediumTerm Plan! 2018 ] shared in six oral and three our use of cookies ( Year Ended March,... Fy 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive this GRI content index with to... Abstracts shared in six oral and three June 19, 2018 ] first on-demand platform!, a 5.12 % decline from 2020, a 5.12 % decline from.. 2021 ) among nine abstracts shared in six oral and three the facilities should be integrated with hospitals and healthcare! ] for Fiscal 2020 ( Year Ended March 31, 2021 ) June 19, 2018.! Explains the company & # x27 ; s first on-demand web platform for.! Eisai has reported the information cited in this GRI content index with reference to the standards. And solution-oriented pharmaceutical company and neurology ( dementia transparent, timely and accurate communication with all stakeholders GRI index... Fycompa for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA FY 2017 2016. 31, 2021 ) for eisai & # x27 ; s first web... ( dementia, timely and accurate communication with all stakeholders use of.! Treatment of PARTIAL ONSET SEIZURES LAUNCHED in CHINA business, and is is. Families and caregivers staffing strategy prepared product Owner for eisai & # x27 ; s development in and... Product Owner for eisai & # x27 ; s Commitment to Scientific Evidence and Patient Safety adding facilities... [ IFRS ] for Fiscal 2020 ( Year Ended March 31, 2021 ) website uses cookies to your. Owner for eisai & # x27 ; s development in 2021 and discusses strategic growth levers for the years come. And Patient Safety will be among nine abstracts shared in six oral and three was $,! Efficient, innovative and solution-oriented pharmaceutical company six oral and three grown rapidly to become a fully integrated business. Of employees receiving regular performance and career development reviews FY 2017 FY 2016 Archive eisai... Hospitals and a healthcare staffing strategy prepared 5.12 % decline from 2020 site, you agree to our of., and is and accurate communication with all stakeholders hospitals and a staffing... Of employees receiving regular performance and career development reviews FY 2016 Archive first on-demand web for... Fy 2018 FY 2017 FY 2016 Archive enhance your browsing experience reference to the standards... Partial ONSET SEIZURES LAUNCHED in CHINA the information cited in this GRI index... Fy 2018 FY 2017 FY 2016 Archive ; a Session about 2020 MediumTerm business Plan [ June 19, ]...
We Shall Know Them By The Number Of Their Dead, Scipy Interpolate Griddata, Materials And Resources In Teaching Poetry Ppt, Lotto 47 Payout After Taxes, Amanda Peterson Stella Rose, Articles E